WuXi TIDES · A WuXi AppTec platform
Discovery, CMC development and the entire manufacturing supply chain for TIDES molecules — under one roof, one quality system, one continuous scale from nanomole to metric tonne.
About Us
WuXi TIDES, a unique Contract Research and Development Manufacturing Organization platform, is an integral part of WuXi AppTec. We offer worldwide partners efficient, flexible and high-quality solutions for the drug development of oligonucleotides, peptides and related synthetic conjugates.
Over 1,600 scientists across 10 R&D and manufacturing sites deliver discovery synthesis, process development and manufacturing of novel monomers, linkers and ligands, oligonucleotides, peptides and complex synthetic conjugates at any scale. Beyond chemistry we offer formulation development, manufacturing, packaging, labeling and distribution in a variety of oral and injectable dosage forms and filling formats.
Our comprehensive analytical method development, validation and testing platform supports TIDES drug development from discovery through clinical to commercial for both drug substance and drug product — and our regulatory dossier teams are experienced in global filings with all major agencies.
Modalities
Oligonucleotides and peptides share our chemistry, our analytics and our quality system — which is exactly why the conjugates between them are the easiest part of the conversation.
High-throughput library and custom synthesis from nmol to mol — ASO, siRNA, sgRNA, PMO, aptamers and their monomers, linkers and ligands.
Linear, cyclic and highly modified peptides with over 100,000 L of total SPPS reactor volume behind them, plus UAA, linkers and toxins.
3,234 amidites, unnatural amino acids and NTPs on the shelf — structures, purity, SDS and list prices, from the quality system that runs GMP supply.
The candidate journey
An integrated CMC platform means the team that made your first hundred milligrams is still on the file when you validate at tonne scale.
High-throughput library and custom synthesis, conjugation, monomer and ligand design with dedicated analytical support.
Route scouting, pre-formulation and tox supply — moving grams to kilograms without changing partners.
Process development, GMP API, drug product and the CMC package that carries an IND across major agencies.
Process validation, scale-up into dedicated suites and stability programmes run under one global quality system.
Validated commercial supply across China, Singapore, Switzerland and the United States, with dual-site redundancy.
Process R&D, API and intermediates manufacturing at any scale.
Pre-formulation, formulation and process development, oral and injectable manufacturing.
Method development and validation, quality control, characterisation and stability.
Dossier preparation supporting global regulatory filings for TIDES molecules.
Why WuXi TIDES
The advantages compound: one quality system, one analytical platform, one set of scientists who already know the molecule.
From discovery to commercialisation entirely within WuXi TIDES, with readily available large R&D and manufacturing capacity.
Seamless collaboration across the oligonucleotide, peptide and small molecule teams — the conjugates nobody else wants to touch.
Biocatalysis for gRNA synthesis, thin film evaporation, reactor-in-series with PAT, continuous flow chromatography, TFF.
One quality system across every site, approved by the major regulatory agencies around the world.
Method development and validation, IPC and release testing, characterisation and stability under one roof.
API and formulation development, manufacturing, analytical, dossier preparation and clinical supply as a single programme.
Meeting global quality standards
One quality system across every site — and the inspection record to show that it holds wherever your filing lands.
Global network
Drag the globe, or hover a site to trace how a molecule moves between them.
What's new
Case studies, inspection outcomes and capacity news from the TIDES platform.
Process mass intensity (PMI) is one of the most important metrics in sustainable manufacturing. It measures the total mass of raw materials required to produce a given mass of product. In…
View now
As GLP-1 receptor agonists continue to redefine treatment for metabolic diseases, drug developers are racing to bring new and more complex therapies to the clinic. But innovation alone is…
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences…
Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life…
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA